

Jason M Springer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4264703/publications.pdf>

Version: 2024-02-01

26
papers

879
citations

840119

11
h-index

610482

24
g-index

28
all docs

28
docs citations

28
times ranked

481
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1366-1383.	2.9	249
2	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1349-1365.	2.9	231
3	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2021, 73, 1088-1105.	1.5	90
4	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis Care and Research</i> , 2021, 73, 1071-1087.	1.5	61
5	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in <i>ADA2</i> . <i>Arthritis and Rheumatology</i> , 2021, 73, 512-519.	2.9	34
6	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. <i>Arthritis and Rheumatology</i> , 2021, 73, 1384-1393.	2.9	32
7	Development and validation of case-finding algorithms for the identification of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis in large healthcare administrative databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1368-1374.	0.9	29
8	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. <i>American Journal of Human Genetics</i> , 2021, 108, 84-99.	2.6	26
9	Giant Cell Arteritis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. <i>ACR Open Rheumatology</i> , 2021, 3, 429-441.	0.9	20
10	Intra cranial granulomatous disease in common variable immunodeficiency: Case series and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 890-896.	1.6	16
11	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. <i>Arthritis Care and Research</i> , 2021, 73, 1061-1070.	1.5	15
12	Clinical Characteristics of an Internet-Based Cohort of Patient-Reported Diagnosis of Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Observational Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e17231.	2.1	13
13	Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. <i>ACR Open Rheumatology</i> , 2021, 3, 101-110.	0.9	12
14	Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta-Analysis of Benefits and Harms of Common Treatments. <i>ACR Open Rheumatology</i> , 2021, 3, 196-205.	0.9	10
15	Takayasu Arteritis: a Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. <i>ACR Open Rheumatology</i> , 2021, 3, 80-90.	0.9	9
16	Protective Role of Mast Cells in Primary Systemic Vasculitis: A Perspective. <i>Frontiers in Immunology</i> , 2017, 8, 990.	2.2	6
17	Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments. <i>ACR Open Rheumatology</i> , 2021, 3, 91-100.	0.9	6
18	A Rare Case of Adenosine Deaminase 2 Deficiency Presenting With Temporal Arteritis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e251-e252.	0.5	6

#	ARTICLE	IF	CITATIONS
19	Polyarteritis nodosa: an evolving primary systemic vasculitis. <i>Postgraduate Medicine</i> , 2023, 135, 61-68.	0.9	5
20	Mast Cell Degranulation Decreases Lipopolysaccharide-Induced Aortic Gene Expression and Systemic Levels of Interleukin-6 In Vivo. <i>Mediators of Inflammation</i> , 2019, 2019, 1-7.	1.4	2
21	Kawasaki Disease: A Systematic Review and Meta-Analysis of Benefits and Harms of Common Treatments. <i>ACR Open Rheumatology</i> , 2021, 3, 671-683.	0.9	2
22	Diagnostic and Therapeutic Challenges of Vasculitis. <i>Canadian Journal of Cardiology</i> , 2022, 38, 623-633.	0.8	2
23	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	0.6	2
24	Dose-dependent Pharmacological Response to Rituximab in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.210361.	1.0	1
25	THU0506...MAST CELL DEFICIENCY AMPLIFIES INFLAMMATORY RESPONSE IN A MOUSE MODEL OF KAWASAKI DISEASE. , 2019, , .		0
26	FC057: Incidence of Infections in the Avacopan Group Versus Prednisone Group in Anca-Associated Vasculitis, Results from the Phase 3 Advocate Study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0